The boswellia market standardizes on AKBA. The other 4 boswellic acids might be more interesting.

Alpha-boswellic acid, beta-boswellic acid, 11-keto-beta-boswellic acid, acetyl-beta-boswellic acid, each with different 5-LOX inhibition profiles and selectivity for downstream mediators. A boswellia extract optimized for microglial inflammation (brain) rather than systemic 5-LOX would be a different product, different IP, different market.Publications of Interest:https://pubmed.ncbi.nlm.nih.gov/1602379/, https://pubmed.ncbi.nlm.nih.gov/19374837/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12669112/